Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Interpretation of TEG Studies in Management of a Severe Glanzmann Thrombasthenia Patient

Paulette Bryant, MD, Katie Andricopulos, PharmD, BCPPS

Blood (2017) 130 (Supplement 1): 4854.

https://doi.org/10.1182/blood.V130.Suppl_1.4854.4854

Published: 2017

Journal Articles

Large Cohort of Symptomatic Female Carriers of Hemophilia in an Extended Native American Family

Becki Berkowitz, RN, CPON, Amber Federizo, RN, MSN, FNP-BC, Garrett E. Bergman, MD MBA, Paula J. Ulsh, RN, BSN

Blood (2015) 126 (23): 4700.

https://doi.org/10.1182/blood.V126.23.4700.4700

Published: 2015

Journal Articles

Safety and Effectiveness of Desmopressin for the Management of Delivery and Major Surgery in Patients with Mild-Moderate Von Willebrand Disease: Final Analysis of the Prodeswil Study

Augusto Bramante Federici, MD, Giancarlo Castaman, MD, Alfonso Iorio, MD PhD, Emily Oliovecchio, Prodeswil Investigators

Blood (2015) 126 (23): 759.

https://doi.org/10.1182/blood.V126.23.759.759

Published: 2015

Journal Articles

A Prospective Comparision of Intranasal (I.N.) and Subcutaneous (S.C.) Desmopressin (DDAVP) Therapy in Type 2M Von Willebrand Disease (VWD).

Scott Herbert, MD, Rekha Parameswaran, MD, Amy D. Shapiro, MD, Jorge Di Paola, MD, Jon Winay, Chris Roberson, Anne Greist, MD

Blood (2006) 108 (11): 1035.

https://doi.org/10.1182/blood.V108.11.1035.1035

Published: 2006

Journal Articles

Inapparent Von Willebrand Disease as the Underlying Cause of Menorrhagia Attributed to Uterine Fibroids.

Tarek Mohamed, MD, Tatyana Sycheva, MD, Douglas R. Schneider, MD, Swati R. Chokalingam, MD, Robert Weinstein, MD

Blood (2005) 106 (11): 4084.

https://doi.org/10.1182/blood.V106.11.4084.4084

Published: 2005

Journal Articles

High Dose Intranasal Desmopressin (DDAVP) Therapy in Type 2M Von Willebrand Disease (VWD): A Prospective Open Label Trial.

Rekha Parameswaran, MD, Jorge Di Paola, MD, Lorrie Miller-Rice, MD, Anne Greist, MD, Amy D. Shapiro, MD

Blood (2005) 106 (11): 1783.

https://doi.org/10.1182/blood.V106.11.1783.1783

Published: 2005

NARROW

Interpretation of TEG Studies in Management of a Severe Glanzmann Thrombasthenia Patient

Large Cohort of Symptomatic Female Carriers of Hemophilia in an Extended Native American Family

Safety and Effectiveness of Desmopressin for the Management of Delivery and Major Surgery in Patients with Mild-Moderate Von Willebrand Disease: Final Analysis of the Prodeswil Study

A Prospective Comparision of Intranasal (I.N.) and Subcutaneous (S.C.) Desmopressin (DDAVP) Therapy in Type 2M Von Willebrand Disease (VWD).

Inapparent Von Willebrand Disease as the Underlying Cause of Menorrhagia Attributed to Uterine Fibroids.

High Dose Intranasal Desmopressin (DDAVP) Therapy in Type 2M Von Willebrand Disease (VWD): A Prospective Open Label Trial.

Email alerts

ASH Publications

American Society of Hematology

Interpretation of TEG Studies in Management of a Severe Glanzmann Thrombasthenia Patient

Large Cohort of Symptomatic Female Carriers of Hemophilia in an Extended Native American Family

Safety and Effectiveness of Desmopressin for the Management of Delivery and Major Surgery in Patients with Mild-Moderate Von Willebrand Disease: Final Analysis of the Prodeswil Study

A Prospective Comparision of Intranasal (I.N.) and Subcutaneous (S.C.) Desmopressin (DDAVP) Therapy in Type 2M Von Willebrand Disease (VWD).

Inapparent Von Willebrand Disease as the Underlying Cause of Menorrhagia Attributed to Uterine Fibroids.

High Dose Intranasal Desmopressin (DDAVP) Therapy in Type 2M Von Willebrand Disease (VWD): A Prospective Open Label Trial.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only